Roflumilast 0.05% (Zoryve), a topical phosphodiesterase-4 inhibitor, is currently approved for treating mild-to-moderate AD in children aged 2 years or older; it was approved for ...
FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 ...
Marin Independent Journal on MSN
Novato dementia drug startup gets venture capital infusion
A Novato startup company that is researching the connection between Alzheimer’s disease and a bacteria found in gum disease ...
AirPods Pro are now an FDA cleared hearing aid for mild to moderate hearing loss, at a fraction of the cost of prescription ...
Manchester will experience sunny skies and mild temperatures this week. Today's high will reach approximately 27 degrees ...
Tyrone Daley stands accused on Monday of sexually abusing his co-worker’s daughter for about three years in an employees’ ...
Approved St John’s wort may benefit selected patients with mild-to-moderate depression, but clinicians should review ...
Compression socks are a simple fix to improve circulation and to keep your lower extremities feeling energized. They come in ...
In the INTEGUMENT-INFANT trial, 34.4% of patients achieved vIGA-AD success and 58.3% reached EASI-75 at week 4.
Trial findings challenge concerns over early rhythm control in patients with mild to moderate chronic kidney disease (CKD) and recent atrial fibrillation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results